1. Home
  2. BDTX vs IDE Comparison

BDTX vs IDE Comparison

Compare BDTX & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDTX
  • IDE
  • Stock Information
  • Founded
  • BDTX 2014
  • IDE 2010
  • Country
  • BDTX United States
  • IDE United States
  • Employees
  • BDTX N/A
  • IDE N/A
  • Industry
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • IDE Finance/Investors Services
  • Sector
  • BDTX Health Care
  • IDE Finance
  • Exchange
  • BDTX Nasdaq
  • IDE Nasdaq
  • Market Cap
  • BDTX 181.4M
  • IDE 177.2M
  • IPO Year
  • BDTX 2020
  • IDE N/A
  • Fundamental
  • Price
  • BDTX $2.93
  • IDE $11.88
  • Analyst Decision
  • BDTX Strong Buy
  • IDE
  • Analyst Count
  • BDTX 6
  • IDE 0
  • Target Price
  • BDTX $14.83
  • IDE N/A
  • AVG Volume (30 Days)
  • BDTX 969.2K
  • IDE 33.5K
  • Earning Date
  • BDTX 08-05-2025
  • IDE 01-01-0001
  • Dividend Yield
  • BDTX N/A
  • IDE 8.83%
  • EPS Growth
  • BDTX N/A
  • IDE N/A
  • EPS
  • BDTX 0.09
  • IDE N/A
  • Revenue
  • BDTX $70,000,000.00
  • IDE N/A
  • Revenue This Year
  • BDTX N/A
  • IDE N/A
  • Revenue Next Year
  • BDTX N/A
  • IDE N/A
  • P/E Ratio
  • BDTX $33.20
  • IDE N/A
  • Revenue Growth
  • BDTX N/A
  • IDE N/A
  • 52 Week Low
  • BDTX $1.20
  • IDE $8.61
  • 52 Week High
  • BDTX $6.75
  • IDE $10.46
  • Technical
  • Relative Strength Index (RSI)
  • BDTX 56.77
  • IDE 69.71
  • Support Level
  • BDTX $3.02
  • IDE $11.79
  • Resistance Level
  • BDTX $3.28
  • IDE $11.90
  • Average True Range (ATR)
  • BDTX 0.19
  • IDE 0.08
  • MACD
  • BDTX -0.01
  • IDE 0.00
  • Stochastic Oscillator
  • BDTX 53.33
  • IDE 93.94

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: